Literature DB >> 16159834

Impact of mitral valve regurgitation evaluated by intraoperative transesophageal echocardiography on long-term outcomes after coronary artery bypass grafting.

Jacob N Schroder1, Matthew L Williams, Jonathan A Hata, Lawrence H Muhlbaier, Madhav Swaminathan, Joseph P Mathew, Donald D Glower, Christopher M O'Connor, Peter K Smith, Carmelo A Milano.   

Abstract

BACKGROUND: It is unclear if mild or moderate mitral valve regurgitation (MR) should be repaired at the time of coronary artery bypass grafting (CABG). We sought to determine the long-term effect of uncorrected MR, measured by intraoperative transesophageal echocardiography (TEE), in CABG patients. METHODS AND
RESULTS: Between May 1999 and September 2003, data were gathered for 3264 consecutive patients who underwent isolated CABG and had MR graded by intraoperative TEE. MR was graded on the following 5 levels: none, trace, mild, moderate, and severe. Patients who had severe MR or who underwent mitral valve surgery were eliminated from the analysis. The remaining patients were combined into the following 3 groups: none or trace, mild, and moderate MR. Preoperative and follow-up data were 99% complete. The median length of follow-up was 3.0 years. Multivariable analysis controlling for important preoperative risk factors was performed to determine predictors of death and death/hospitalization for heart failure. Increasing MR was a risk factor for death [hazard ratio (HR), 1.44; P<0.001] and death/heart failure hospitalization (HR, 1.34; P<0.01). When patients with moderate MR were eliminated from the analysis, mild MR was a risk factor for death (HR, 1.34; P=0.011) and death/hospitalization for heart failure (HR, 1.34; P<0.001).
CONCLUSIONS: Even mild MR, identified by intraoperative TEE, predicts worse outcomes after CABG. Revascularization alone did not eliminate the negative long-term effects of mild MR. CABG patients with uncorrected mild or moderate MR are at increased risk for death and heart-failure hospitalization; consideration for surgical repair or more aggressive medical management and follow-up is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16159834     DOI: 10.1161/CIRCULATIONAHA.104.523472

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  20 in total

Review 1.  Intraoperative echocardiography in valvular heart disease: an evidence-based appraisal.

Authors:  Hector I Michelena; Martin D Abel; Rakesh M Suri; William K Freeman; Roger L Click; Thoralf M Sundt; Hartzell V Schaff; Maurice Enriquez-Sarano
Journal:  Mayo Clin Proc       Date:  2010-07       Impact factor: 7.616

2.  Surgical options for the management of ischemic cardiomyopathy.

Authors:  Robert Michler
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-10

3.  Myocardial perfusion pattern for stratification of ischemic mitral regurgitation response to percutaneous coronary intervention.

Authors:  Parag Goyal; Jiwon Kim; Attila Feher; Claudia L Ma; Sergey Gurevich; David R Veal; Massimiliano Szulc; Franklin J Wong; Mark B Ratcliffe; Robert A Levine; Richard B Devereux; Jonathan W Weinsaft
Journal:  Coron Artery Dis       Date:  2015-12       Impact factor: 1.439

4.  Computational modeling of pathophysiologic responses to exercise in Fontan patients.

Authors:  Ethan Kung; James C Perry; Christopher Davis; Francesco Migliavacca; Giancarlo Pennati; Alessandro Giardini; Tain-Yen Hsia; Alison Marsden
Journal:  Ann Biomed Eng       Date:  2014-09-27       Impact factor: 3.934

5.  Surgical treatment of moderate ischemic mitral regurgitation.

Authors:  Peter K Smith; John D Puskas; Deborah D Ascheim; Pierre Voisine; Annetine C Gelijns; Alan J Moskowitz; Judy W Hung; Michael K Parides; Gorav Ailawadi; Louis P Perrault; Michael A Acker; Michael Argenziano; Vinod Thourani; James S Gammie; Marissa A Miller; Pierre Pagé; Jessica R Overbey; Emilia Bagiella; François Dagenais; Eugene H Blackstone; Irving L Kron; Daniel J Goldstein; Eric A Rose; Ellen G Moquete; Neal Jeffries; Timothy J Gardner; Patrick T O'Gara; John H Alexander; Robert E Michler
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

6.  Impact of Left Ventricular to Mitral Valve Ring Mismatch on Recurrent Ischemic Mitral Regurgitation After Ring Annuloplasty.

Authors:  Romain Capoulade; Xin Zeng; Jessica R Overbey; Gorav Ailawadi; John H Alexander; Deborah Ascheim; Michael Bowdish; Annetine C Gelijns; Paul Grayburn; Irving L Kron; Robert A Levine; Michael J Mack; Serguei Melnitchouk; Robert E Michler; John C Mullen; Patrick O'Gara; Michael K Parides; Peter Smith; Pierre Voisine; Judy Hung
Journal:  Circulation       Date:  2016-10-25       Impact factor: 29.690

7.  Posterior papillary muscle anchoring affects remote myofiber stress and pump function: finite element analysis.

Authors:  Joe Luis Pantoja; Liang Ge; Zhihong Zhang; William G Morrel; Julius M Guccione; Eugene A Grossi; Mark B Ratcliffe
Journal:  Ann Thorac Surg       Date:  2014-08-15       Impact factor: 4.330

Review 8.  Multimodality imaging assessment of mitral valve anatomy in planning for mitral valve repair in secondary mitral regurgitation.

Authors:  Romain Capoulade; Nicolas Piriou; Jean-Michel Serfaty; Thierry Le Tourneau
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

9.  Surgical revascularization is associated with maximal survival in patients with ischemic mitral regurgitation: a 20-year experience.

Authors:  Anthony W Castleberry; Judson B Williams; Mani A Daneshmand; Emily Honeycutt; Linda K Shaw; Zainab Samad; Renato D Lopes; John H Alexander; Joseph P Mathew; Eric J Velazquez; Carmelo A Milano; Peter K Smith
Journal:  Circulation       Date:  2014-04-17       Impact factor: 29.690

10.  Repair or observe moderate ischemic mitral regurgitation during coronary artery bypass grafting? Prospective randomized multicenter data.

Authors:  Brian C Gulack; Brian R Englum; Anthony W Castleberry; Mani A Daneshmand; Peter K Smith; Louis P Perrault
Journal:  Ann Cardiothorac Surg       Date:  2015-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.